Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2026
Metabolic Phenotype-Stratified Associations Between Obesity/Overweight and Mortality in Peritoneal Dialysis Patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shang Sijia, Zhao Guowen, Tian Na, Zhan Xiaojiang, Peng Fenfen, Wang Xiaoyang, Wen Yueqiang, Xu Qingdong, Feng Xiaoran, Tang Xingming, Wu Xianfeng, Zhou Qian, Zhang Xing, Su Ning
Аннотация
BACKGROUND: Metabolic abnormalities and obesity/overweight are prevalent in peritoneal dialysis (PD) patients, and their interplay may significantly impact clinical outcomes. This study aimed to investigate the association between metabolic phenotypes (stratified by body mass index [BMI] and metabolic status) and all-cause mortality in PD patients.
METHODS: This multicenter cohort study was conducted from January 1, 2001, to May 31, 2023. Participants were categorized into four metabolic phenotypes based on their BMI and metabolic status: Metabolically Healthy Overweight/Obesity (MHO), Metabolically Healthy Non-Overweight/Obesity (MHNO), Metabolically Unhealthy Overweight/Obesity (MUO), Metabolically Unhealthy Non-Overweight/Obesity (MUNO). The primary outcome is all-cause mortality. Cox regression analysis was employed to evaluate the association between metabolic phenotypes and all-cause mortality.
RESULTS: The study cohort comprised 4305 participants, with 1034 deaths during follow-up. Compared with the MHNO subgroup patients, those in the MUNO subgroup (HR, 1.169; 95%CI, 1.007-1.356) and the MUO subgroup (HR, 1.206; 95% CI, 1.013-1.437) exhibited a higher risk of all-cause mortality, whereas patients in the MHO group did not show an increased risk (HR, 0.921; 95% CI, 0.718-1.181). These results were consistent in subgroup and sensitivity analyses.
CONCLUSION: In this cohort study, we found that patients with metabolic abnormalities showed a higher risk of all-cause mortality. The influence of BMI on all-cause mortality in PD patients varies with metabolic status; thus, metabolic status should be prioritized in risk stratification and personalized management for PD patients with overweight/obesity.
METHODS: This multicenter cohort study was conducted from January 1, 2001, to May 31, 2023. Participants were categorized into four metabolic phenotypes based on their BMI and metabolic status: Metabolically Healthy Overweight/Obesity (MHO), Metabolically Healthy Non-Overweight/Obesity (MHNO), Metabolically Unhealthy Overweight/Obesity (MUO), Metabolically Unhealthy Non-Overweight/Obesity (MUNO). The primary outcome is all-cause mortality. Cox regression analysis was employed to evaluate the association between metabolic phenotypes and all-cause mortality.
RESULTS: The study cohort comprised 4305 participants, with 1034 deaths during follow-up. Compared with the MHNO subgroup patients, those in the MUNO subgroup (HR, 1.169; 95%CI, 1.007-1.356) and the MUO subgroup (HR, 1.206; 95% CI, 1.013-1.437) exhibited a higher risk of all-cause mortality, whereas patients in the MHO group did not show an increased risk (HR, 0.921; 95% CI, 0.718-1.181). These results were consistent in subgroup and sensitivity analyses.
CONCLUSION: In this cohort study, we found that patients with metabolic abnormalities showed a higher risk of all-cause mortality. The influence of BMI on all-cause mortality in PD patients varies with metabolic status; thus, metabolic status should be prioritized in risk stratification and personalized management for PD patients with overweight/obesity.